Acute Coronary Syndrome News and Research

RSS

CVD/MI complications tend to occur within first 30 days after PCI

Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open.

26 Mar 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

Inconsistent results from ACS and depression studies

Although it is still suggested that acute coronary syndrome patients with first and new-onset depression are at particularly increased risk of worse prognosis, the inconsistent results from the studies included in this systematic review show that there is no consistent evidence to support such statements.

3 Mar 2012

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That’s three months later than originally scheduled.

2 Mar 2012

BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB and its collaborator Genentech, a member of the Roche Group, announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease.

2 Mar 2012

Positive results from Critical Diagnostics' biomarker study in ambulatory heart failure patients

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model.

29 Feb 2012

Initial stent implantation does not appear to improve outcomes for patients with stable CAD

A meta-analysis of eight previously published clinical trials suggests that initial stent implantation for patients with stable coronary artery disease is not associated with improved outcomes compared with initial medical therapy for prevention of death, nonfatal heart attacks, unplanned revascularization or angina, according to a study published in the Feb. 27 Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

Research roundup: Hospital medication errors; Key Medicaid issues in 2014

Use Of Preventive Services Could Be Better Aligned With Clinical Recommendations -- This report looks at Medicare patients' use of eight specific preventive services, which have "the potential to improve health outcomes and lower health care expenditures," according to the authors. Use of cardiovascular and cervical cancer screenings "generally aligned with clinical recommendations, ... but use of other cancer screenings" did not.

24 Feb 2012

Report addresses treatment preferences among depressed patients after heart attack

A report in the last 2011 issue of Psychotherapy and Psychosomatics addresses the treatment preferences that are expressed by depressed patients after a heart attack.

13 Feb 2012

Top-line results from Merck's vorapaxar clinical study on thrombosis

Merck, known outside the United States and Canada as MSD, today announced the top-line results of the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events) study of vorapaxar.

7 Feb 2012

Coronary patients with low levels of anti-PC at greater risk of complications

Coronary patients with low levels of an immune system antibody called anti-PC, which neutralises parts of the "bad" cholesterol, run a greater risk of suffering complications following an acute cardiac episode and thus of premature death.

6 Feb 2012

Aspirin may reduce depressive symptoms in survivors of ACS

Aspirin has been commonly used for prevention of cardiovascular disease. Depression has been found to be an important prognostic factor after heart attacks. But what is their relationship? This is addressed by a study published in the 5th 2011 issue of Psychotherapy and Psychosomatics.

24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Troponin I level test may help rule-out diagnosis of heart attack

For patients admitted to an emergency department with chest pain, use of a contemporary or highly sensitive test for levels of troponin I (a protein in muscle tissue) may help rule-out a diagnosis of heart attack, while changes in the measured levels of this biomarker at 3 hours after admission may be useful to confirm a diagnosis of heart attack, according to a study in the December 28 issue of JAMA.

28 Dec 2011

ESC, SAGE to launch European Heart Journal: Acute Cardiovascular Care

SAGE and the European Society of Cardiology (ESC) have announced the launch of the European Heart Journal: Acute Cardiovascular Care.

19 Dec 2011

ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.

13 Dec 2011